Literature DB >> 19454499

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.

Laura Chiecchio1, Gian Paolo Dagrada, Rebecca K M Protheroe, David M Stockley, Alastair G Smith, Kim H Orchard, Nicholas C P Cross, Christine J Harrison, Fiona M Ross.   

Abstract

We report serial genetic studies on a young female patient initially diagnosed with asymptomatic smouldering myeloma who progressed to symptomatic myeloma 4.5 years after presentation. An unbalanced translocation, der(14)t(4;14)(p16;q32), was initially found in all plasma cells plus deletions of other chromosomal regions as detected by array-based comparative genomic hybridization. Deletion of chromosome 13 was observed in a minor population of plasma cells (<20%) for the first two years, increasing to 100% of plasma cells by the time of multiple myeloma diagnosis. Loss of 1p and a rearrangement of MYC were first observed in a small population of plasma cells one year prior to the clinical diagnosis of multiple myeloma, but these subclones increased rapidly in size to become the major population suggesting that they were directly involved in the transformation process. This case report provides a unique insight into the mechanisms of disease progression from smouldering multiple myeloma to multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454499      PMCID: PMC2704316          DOI: 10.3324/haematol.2008.004440

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  23 in total

1.  Guidelines on the diagnosis and management of multiple myeloma 2005.

Authors:  Alastair Smith; Finn Wisloff; Diana Samson
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

2.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  Prognostic features of asymptomatic multiple myeloma.

Authors:  D M Weber; M A Dimopoulos; L A Moulopoulos; K B Delasalle; T Smith; R Alexanian
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

4.  Smoldering multiple myeloma.

Authors:  R A Kyle; P R Greipp
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

5.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

6.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Authors:  Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

10.  Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.

Authors:  Amel Dib; Timothy R Peterson; Laura Raducha-Grace; Adriana Zingone; Fenghuang Zhan; Ichiro Hanamura; Bart Barlogie; John Shaughnessy; W Michael Kuehl
Journal:  Cell Div       Date:  2006-10-18       Impact factor: 5.130

View more
  18 in total

1.  Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.

Authors:  Isabella C Glitza; Gary Lu; Rupin Shah; Qaiser Bashir; Nina Shah; Richard E Champlin; Jatin Shah; Robert Z Orlowski; Muzaffar H Qazilbash
Journal:  Leuk Lymphoma       Date:  2014-08-18

Review 2.  Early lymphoid lesions: conceptual, diagnostic and clinical challenges.

Authors:  Karthik A Ganapathi; Stefania Pittaluga; Oreofe O Odejide; Arnold S Freedman; Elaine S Jaffe
Journal:  Haematologica       Date:  2014-09       Impact factor: 9.941

Review 3.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

Review 4.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

5.  RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.

Authors:  Hans C Lee; Hua Wang; Veerabhadran Baladandayuthapani; Heather Lin; Jin He; Richard J Jones; Isere Kuiatse; Dongmin Gu; Zhiqiang Wang; Wencai Ma; John Lim; Sean O'Brien; Jonathan Keats; Jing Yang; Richard E Davis; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2017-04       Impact factor: 6.998

Review 6.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

7.  How I treat smoldering multiple myeloma.

Authors:  Irene M Ghobrial; Ola Landgren
Journal:  Blood       Date:  2014-10-08       Impact factor: 22.113

Review 8.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

9.  The road to cure in multiple myeloma starts with smoldering disease.

Authors:  Karma Z Salem; Irene M Ghobrial
Journal:  Expert Opin Orphan Drugs       Date:  2015-04-12       Impact factor: 0.694

10.  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma.

Authors:  Neeraj Sharma; James B Smadbeck; Nadine Abdallah; Cinthya Zepeda-Mendoza; Moritz Binder; Kathryn E Pearce; Yan W Asmann; Jess F Peterson; Rhett P Ketterling; Patricia T Greipp; P Leif Bergsagel; S Vincent Rajkumar; Shaji K Kumar; Linda B Baughn
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.